CAMBRIDGE, England & EDINBURGH, Scotland--(BUSINESS WIRE)--Axol Bioscience Ltd. (Axol), an established provider of iPSC-derived cells, media, and characterization services for life science discovery, ...

Axol Bioscience’s CiPA-validated ventricular cardiomyocytes can be used as a robust cardiotoxicity measurement tool. Axol Bioscience, a provider of induced pluripotent stem cell (ISPC)-derived cells, ...

CAMBRIDGE, England--(BUSINESS WIRE)--Axol Bioscience Ltd. (Axol), an established provider of iPSC-derived cells, media, and characterization services for life science discovery, today announced that ...

Axol Bioscience Ltd. (Axol), a leading pluripotent stem cell technology provider for drug discovery has signed an exclusive agreement with StrataStem to access and commercialize its extensive ...

Companies will incorporate cells and technology to create a ‘clinical trial in a dish’ Companies will incorporate cells and technology to create a ‘clinical trial in a dish’ Axol Bioscience – a stem ...

Axol Bioscience and Censo Biotechnologies have merged to set up a one-stop-shop for induced pluripotent stem cells (iPSCs). IPSCs are derived from skin or blood cells that have been reprogrammed back ...

Sygnature Discovery, a world-leading integrated drug discovery provider and non-clinical solutions provider, has announced a scientific collaboration with human induced pluripotent stem cell (iPSC) ...

The private equity funding will enable the startup biotech firm to expand product development as well as sales and marketing capabilities. On August 15, 2017, Calculus Capital (London), a private ...